Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients...
Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cellsGradalis applies a novel clinically relevant...
Aims to raise vital funding for the iStopMM Project and Other IMF Research InitiativesSTUDIO CITY, Calif., March 13, 2025 (GLOBE...
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples...
Astronauts to Support Cutting-Edge Biomedical Investigations, NSF-Funded Physical Science Projects, and More Through the ISS National Lab KENNEDY SPACE CENTER,...
Astronauts to Support Cutting-Edge Biomedical Investigations, NSF-Funded Physical Science Projects, and More Through the ISS National Lab KENNEDY SPACE CENTER,...
Setting the standard through dynamic genomic technology platform, improving patient outcomes AURORA, Colo., March 12, 2025 /PRNewswire/ -- The Children's...
Setting the standard through dynamic genomic technology platform, improving patient outcomes AURORA, Colo., March 12, 2025 /PRNewswire/ -- The Children's...
Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March...
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death...
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company...
LONG BEACH, Calif. and TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")...
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the...
Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated...
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO, March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq:...
Revolutionizing Law Enforcement, Medical and Military Applications STUART, Fla., March 10, 2025 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT), a...
MILAN and TEL HASHOMER, Israel, March 10, 2025 /PRNewswire/ -- Tethis S.p.A., a pioneer in standardized liquid biopsy platform development, and...
ALBANY, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,...
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Full Circles Therapeutics, a leader in next-generation genome engineering, announces that the United...